Potential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes
Authors' conclusion
Semaglutide in T2D potentially reduces circulating inflammatory monocytes, increases bone marrow retention, and lowers markers of endothelial inflammation, with no reduction in coronary artery inflammatory macrophages.
Study context
- Population
- Individuals with T2DM (mean age 63.2 years, 37.5% female, body mass index (BMI) 28.33 kg/m², HbA1c 78.1 mmol/mol)bone marrow aspirates n = 14
- Participants
- 16 individuals
- Comparison
- After 6 months of semaglutide vs baseline
- Outcome
- Cardiovascular-haematopoietic axis: circulating monocytes and haematopoietic precursors (flow cytometry), plasma cytokines, inflammatory macrophages in coronary arteries, bone marrow and spleen (68Ga-DOTATATE PET-CT)
- Follow-up
- 6 months
Methodological detailssingle-group, before–after (baseline vs 6 months)
- Single-group
- Before–after (baseline vs 6 months)
Main finding
As reported in the abstract
Circulating CD16+ monocytes lower (P = .034)
−18.8%
68Ga-DOTATATE PET-CT bone marrow uptake lower (P = .037)
−17.5%
Further findings
HbA1c, weight, BMI, high-sensitivity C-reactive protein (hsCRP) · 6 months
- HbA1c change (P < .0001)
- −21.1 mmol/mol
- Weight change (P < .001)
- −6.7 kg
- BMI change (P < .001)
- −2.5 kg/m²
- hsCRP change (P = .005)
- −1.0 mg/L
Original publication
Potential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes. Eur Heart J. Published 29 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →